MOLN Molecular Partners AG
Healthcare$4.05-3.11%ClosedMarket Cap: $151.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.73
P/S
0.00
EV/EBITDA
-0.76
DCF Value
$2.73
FCF Yield
-40.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-66.2%
ROA
-66.3%
ROIC
-69.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-17.2M | $-16.8M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-15.8M | $-15.8M | $— | — |
| FY null | $0.00 | NaN% | $-58.1M | $-61.7M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-14.9M | $-14.8M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-17.8M | $-24.7M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-18.0M | $-18.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-14.8M | $-11.2M | $— | — |
| FY null | $5.0M | -855.8% | $-61.2M | $-54.0M | $— | — |
| Q3 null | $681.0K | -1495.3% | $-14.6M | $-16.4M | $— | — |
| Q2 null | $1.6M | -743.8% | $-16.0M | $-15.1M | $— | — |
| Q1 null | $2.7M | -415.1% | $-15.9M | $-11.3M | $— | — |
| Q4 2023 | $1.0M | -1054.1% | $-16.6M | $-19.8M | $-0.60 | — |